SCHEDULE 13G/A: CVI Investments and Heights Capital Management Update Passive Stake in Reviva Pharmaceuticals to 4.9%

CVI Investments, Inc. and Heights Capital Management, Inc. have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.9% in Reviva Pharmaceuticals Holdings, Inc. as of December 31, 2024.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. (collectively, 'Reporting Persons') filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Reviva Pharmaceuticals Holdings, Inc.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 2,446,376 shares of Reviva Pharmaceuticals' Common Stock.
• This aggregate amount represents 4.9% of the company's outstanding Common Stock.
• Heights Capital Management, Inc. serves as the investment manager to CVI Investments, Inc. and may exercise shared voting and dispositive power over the reported shares.
• The shares reported as beneficially owned consist of shares issuable upon the exercise of warrants to purchase shares.
• The warrants are structured with a limitation, preventing their exercise to the extent that beneficial ownership by a Reporting Person and its affiliates would exceed 4.99% of the outstanding shares.
• Reviva Pharmaceuticals had 46,579,199 shares outstanding as of the completion of an offering referred to in its Prospectus Supplement filed on December 18, 2024.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the perceived value or risk of the company, thus maintaining a neutral sentiment.

Positives

• The continued presence of institutional investors like CVI Investments and Heights Capital Management on the shareholder register, even with a passive stake, indicates a baseline level of institutional interest in Reviva Pharmaceuticals.

Negatives

• The filing indicates a stake of 4.9%, which is below the 5% threshold that typically triggers new Schedule 13G filings. While this is an amendment, it could imply a reduction from a previously higher stake, which some investors might interpret as a negative signal regarding the company's prospects or the investor's conviction, though the document does not explicitly state a reduction or the prior ownership percentage.

Risks

• The warrants held by the Reporting Persons are subject to an exercisability limitation, preventing their exercise if it would result in beneficial ownership exceeding 4.99% of the outstanding shares. This is a compliance measure to avoid triggering certain reporting requirements or control implications.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

Reviva Pharmaceuticals Holdings, Inc. operates in the pharmaceutical industry. This filing provides an update on the passive investment stake held by CVI Investments and Heights Capital Management, which is a common occurrence for publicly traded companies in the biotech and pharmaceutical sectors as institutional investors adjust their portfolios.

Stakeholder Impact

• Shareholders are informed of the current passive ownership stake held by CVI Investments, Inc. and Heights Capital Management, Inc., providing transparency regarding significant institutional holdings.

Key Dates

Keywords

Reviva Pharmaceuticals Holdings Inc, CVI Investments Inc, Heights Capital Management Inc, Schedule 13G, Beneficial Ownership, Passive Investment, Common Stock, Warrants, Pharmaceuticals, Biotechnology